AI Article Synopsis
- Liver adenomas are benign tumors that can turn malignant, and researchers discovered a specific deletion in chromosome 12q in several adenomas.
- This deletion targets a region associated with the TCF1 gene, which is linked to a form of diabetes, suggesting that TCF1 may act as a tumor-suppressor gene.
- The study found that inactivation of TCF1 is a significant genetic factor in liver adenoma development and could be an early indicator for some cases of hepatocellular carcinoma (HCC).
Article Abstract
Liver adenomas are benign tumors at risk of malignant transformation. In a genome-wide search for loss of heterozygosity (LOH) associated with liver adenomas, we found a deletion in chromosome 12q in five of ten adenomas. In most cases, LOH at 12q was the only recurrent genetic alteration observed, suggesting the presence of a tumor-suppressor gene in that region. A minimal common region of deletion was defined in 12q24 that included the gene TCF1 (transcription factor 1), encoding hepatocyte nuclear factor 1 (HNF1; refs 1,2). Heterozygous germline mutations of TCF1 have been identified in individuals affected with maturity-onset diabetes of the young type 3 (MODY3; ref. 3). Bi-allelic inactivation of TCF1 was found in 10 of 16 screened adenomas, and heterozygous germline mutation were present in three affected individuals. Furthermore, 2 well-differentiated hepatocellular carcinomas (HCCs) occurring in normal liver contained somatic bi-allelic mutations of 30 screened HCCs. These results indicate that inactivation of TCF1, whether sporadic or associated with MODY3, is an important genetic event in the occurrence of human liver adenoma, and may be an early step in the development of some HCCs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/ng1001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Stabilization of β-Catenin Directs HEB to Limit Thymic Selection.
J Immunol
September 2024
Department of Immunology, Mayo Clinic, Scottsdale, AZ.
Activation of β-catenin in CD4+CD8+ double-positive (DP) thymocytes halts development before the thymic selection stage and predisposes to transformation. Leukemogenesis, but not the developmental block, depends on TCF-1, β-catenin's DNA-binding partner. In this study, we show that β-catenin activation directs the DNA-binding protein HEB to block DP thymocyte development.
View Article and Find Full Text PDFLiver X receptor controls follicular helper T cell differentiation via repression of TCF-1.
Proc Natl Acad Sci U S A
February 2023
Laboratory of Immune Regulation, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
Liver X receptor (LXR) is a critical regulator of cholesterol homeostasis that inhibits T cell receptor (TCR)-induced proliferation by altering intracellular sterol metabolism. However, the mechanisms by which LXR regulates helper T cell subset differentiation remain unclear. Here, we demonstrate that LXR is a crucial negative regulator of follicular helper T (Tfh) cells in vivo.
View Article and Find Full Text PDFWNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer.
J Exp Med
January 2023
Department of Surgery, University of Michigan, Ann Arbor, MI.
Article Synopsis
- Pancreatic ductal adenocarcinoma (PDA) is linked to WNT signaling activation, which influences the tumor microenvironment.
- Single-cell RNA sequencing of human pancreatic cancer revealed that CD4+ T cells in the tumors express TCF7, affecting immune responses.
- Inhibiting WNT signaling and using a PD-L1 blocker in combination showed promising results in reducing tumor growth, suggesting a potential new treatment approach for PDA.
Isoorientin inhibits epithelial-to-mesenchymal properties and cancer stem-cell-like features in oral squamous cell carcinoma by blocking Wnt/β-catenin/STAT3 axis.
Toxicol Appl Pharmacol
August 2021
Department of Biotechnology and Pharmaceutical Technology, Yuanpei University of Medical Technology, No. 306, Yuanpei Street, Hsinchu, Taiwan. Electronic address:
Oral squamous cell carcinoma (OSCC) is among the most prevalent cancers of the head and neck. This study revealed that isoorientin attenuates OSCC cell stemness and epithelial-mesenchymal transition potential through the inhibition of JAK/signal transducer and activator of transcription 3 (STAT3) and Wnt/β-catenin signaling in cell lines. Our findings indicated that isoorientin is a potential inhibitor of β-catenin/STAT3 in vitro and in vivo.
View Article and Find Full Text PDFEnhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3.
J Immunother Cancer
October 2020
Infection and Immunity, Cardiff University Department of Medicine, Cardiff, UK.
Article Synopsis
- Immunotherapies often fail to effectively enhance cancer-specific T cell responses in patients, but blocking the PI3Kδ enzyme shows promise in improving tumor immunity in early trials.
- In a study using mice with mammary tumors, treatment with a PI3Kδ inhibitor, either alone or in combination with anti-LAG3 antibodies, resulted in significant variations in tumor response, characterized by different levels of T cell activity.
- The combination therapy was successful in treating all mice, highlighting the role of LAG3 in tumor non-regression and suggesting that an initial response to PI3Kδ inhibition is crucial for maximizing the effects of anti-LAG3 treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!